Annotation and evaluation of base editing outcomes in multiple cell types using CRISPRbase
Nucleic Acids Research · 2023
DOI: 10.1093/nar/gkac967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2023. Verfasst von Jibiao Fan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China. Hauptthemen laut MEDLINE: Gene Editing, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Nova Program, Clinical Medicine Plus X - Young Scholars Project, Peking University.
Abstract (Originalsprache)
CRISPR-Cas base editing (BE) system is a powerful tool to expand the scope and efficiency of genome editing with single-nucleotide resolution. The editing efficiency, product purity, and off-target effect differ among various BE systems. Herein, we developed CRISPRbase (http://crisprbase.maolab.org), by integrating 1 252 935 records of base editing outcomes in more than 50 cell types from 17 species. CRISPRbase helps to evaluate the putative editing precision of different BE systems by integrating multiple annotations, functional predictions and a blasting system for single-guide RNA sequences. We systematically assessed the editing window, editing efficiency and product purity of various BE systems. Intensive efforts were focused on increasing the editing efficiency and product purity of base editors since the byproduct could be detrimental in certain applications. Remarkably, more than half of cancer-related off-target mutations were non-synonymous and extremely damaging to protein functions in most common tumor types. Luckily, most of these cancer-related mutations were passenger mutations (4840/5703, 84.87%) rather than cancer driver mutations (863/5703, 15.13%), indicating a weak effect of off-target mutations on carcinogenesis. In summary, CRISPRbase is a powerful and convenient tool to study the outcomes of different base editors and help researchers choose appropriate BE designs for functional studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.
- College of Animal Science and Technology, Yangzhou University, Yangzhou, Jiangsu Province 225009, China.
- Cancer Center, Peking University Third Hospital, Beijing 100191, China.
- Rice Research Institute, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China.
- Guangdong Key Laboratory of New Technology in Rice Breeding, Guangzhou 510640, China.
- Guangdong Rice Engineering Laboratory, Guangzhou 510640, China.
ORCID-Profile: Fengbiao Mao
Förderung
- National Natural Science Foundation of China
- Beijing Nova Program
- Clinical Medicine Plus X - Young Scholars Project, Peking University
- Peking University Third Hospital
- the Project of Collaborative Innovation Center of GDAAS
Zitieren
APA
Fan, J., Shi, L., Liu, Q., Zhu, Z., Wang, F., Song, R., Su, J., Zhou, D., Chen, X., Li, K., Xue, L., Sun, L., & Mao, F. (2023). Annotation and evaluation of base editing outcomes in multiple cell types using CRISPRbase. Nucleic Acids Research. https://doi.org/10.1093/nar/gkac967
Vancouver
Fan J, Shi L, Liu Q, Zhu Z, Wang F, Song R, et al. Annotation and evaluation of base editing outcomes in multiple cell types using CRISPRbase. Nucleic Acids Research. 2023. doi:10.1093/nar/gkac967
BibTeX
@article{Fan2023,
author = {Fan, Jibiao and Shi, Leisheng and Liu, Qi and Zhu, Zhipeng and Wang, Fan and Song, Runxian and Su, Jimeng and Zhou, Degui and Chen, Xiao and Li, Kailong and Xue, Lixiang and Sun, Lichao and Mao, Fengbiao},
title = {Annotation and evaluation of base editing outcomes in multiple cell types using CRISPRbase},
journal = {Nucleic Acids Research},
year = {2023},
doi = {10.1093/nar/gkac967}
}
EUVIMED